Monitoring Py8119 breast cancer cell proliferation in direct cocultures with osteoblasts and osteoclasts
- 1The Center for Translational Medicine, Departments of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
- 2Department of Orthopaedic Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Abstract
The intricate interaction among breast cancer (BrCa) cells, stromal/osteoblastic cells, and osteoclasts in the osseous microenvironment drives a vicious cycle that accelerates both osteolysis and tumor progression. Elucidating how these bone cells directly modulate BrCa cell proliferation is of paramount importance. Due to a lack of intrinsic background of luminescence signal in the body, the luciferase/luciferin assay enables sensitive, in vivo monitoring of tumor progression. However, this technique has not yet been utilized to monitor tumor cell proliferation during direct co-culture with bone cells. In this study, we generated a Py8119 BrCa cell line stably expressing luciferase (luc). We demonstrated that the bioluminescence intensity of Py8119-luc cells strongly correlates with cell proliferation at various time points, validated by both cell counts and BrdU assays. Utilizing this system, we found that both dual cocultures (with osteoblasts) and triple cocultures (with osteoblasts and osteoclasts) promote Py8119-luc cell growth. Notably, a receptor activator of nuclear factor-κB ligand (RANKL)-neutralizing monoclonal antibody suppressed Py8119-luc proliferation in direct cocultures with both osteoblasts and osteoclasts, but not with osteoblasts alone, thereby confirming the feasibility of these cell models. In summary, our in vitro model for luciferase/luciferin assay effectively quantifies tumor cell proliferation in direct dual and triple cocultures with bone cells. These findings highlight the potential of this direct coculture model for screening and evaluating novel therapeutics targeting bone-metastatic breast cancer.
Related
- Deep Learning-Augmented Stimulated Raman Imaging for Cell-Type-Specific Metabolic Profiling in Live Neuronal Cocultures.
- Bisphosphonate zoledronic acid blocks secretory autophagy and inhibits bone resorptive functions in osteoclasts
- ATP6AP2 in osteoblasts couples cortical bone matrix remodeling to osteocyte maturation via MMP14 activation in mice
- Modulatory Effects of the Er,Cr:YSGG—Diode Laser Combination Irradiation on Human Osteoblasts—Might Be Relevant for Periapical Bone Regeneration?
- Effects of Repetitive Compressive Loading on the Expression of Autophagy-Related Factors, Autophagy Capacity and Cellular Activity in Human Subchondral Bone Osteoblasts
BibTeX
@article{yang2026monitoring,
title = {{Monitoring Py8119 breast cancer cell proliferation in direct cocultures with osteoblasts and osteoclasts}},
author = {Yanmei Yang and Bin Wang},
journal = {The Journal of Biological Chemistry},
year = {2026},
month = sep,
doi = {10.1016/j.jbc.2026.113597},
url = {https://doi.org/10.1016/j.jbc.2026.113597},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Monitoring Py8119 breast cancer cell proliferation in direct cocultures with osteoblasts and osteoclasts
AU - Yanmei Yang
AU - Bin Wang
PY - 2026
DA - 2026/09/23
JO - The Journal of Biological Chemistry
DO - 10.1016/j.jbc.2026.113597
UR - https://doi.org/10.1016/j.jbc.2026.113597
AB - The intricate interaction among breast cancer (BrCa) cells, stromal/osteoblastic cells, and osteoclasts in the osseous microenvironment drives a vicious cycle that accelerates both osteolysis and tumor progression. Elucidating how these bone cells directly modulate BrCa cell proliferation is of paramount importance. Due to a lack of intrinsic background of luminescence signal in the body, the luciferase/luciferin assay enables sensitive, in vivo monitoring of tumor progression. However, this technique has not yet been utilized to monitor tumor cell proliferation during direct co-culture with bone cells. In this study, we generated a Py8119 BrCa cell line stably expressing luciferase (luc). We demonstrated that the bioluminescence intensity of Py8119-luc cells strongly correlates with cell proliferation at various time points, validated by both cell counts and BrdU assays. Utilizing this system, we found that both dual cocultures (with osteoblasts) and triple cocultures (with osteoblasts and osteoclasts) promote Py8119-luc cell growth. Notably, a receptor activator of nuclear factor-κB ligand (RANKL)-neutralizing monoclonal antibody suppressed Py8119-luc proliferation in direct cocultures with both osteoblasts and osteoclasts, but not with osteoblasts alone, thereby confirming the feasibility of these cell models. In summary, our in vitro model for luciferase/luciferin assay effectively quantifies tumor cell proliferation in direct dual and triple cocultures with bone cells. These findings highlight the potential of this direct coculture model for screening and evaluating novel therapeutics targeting bone-metastatic breast cancer.
SN - 0021-9258
SN - 1083-351X
ER -